The derivative company completed a 150 million yuan Series A financing to accelerate the clinical progress of the core pipeline and upgrade the technology platform.

Recently, Chengdu Xianyi Biotechnology Co., Ltd. announced the completion of a 150 million yuan Series A financing. This round of financing was led by Daoyuan Capital, with joint lead investment from Qishen Venture Capital, Jiale Capital, Chengdu Science and Technology Investment Group, Sichuan Province Pilot R&D Co., Ltd., Xiamen High-tech Investment, Zeng Rui Minghe, and other follow-up investors. Existing shareholders Chengdu Leading, Yinman Fund, Huaike Capital, Juntian Venture Capital, Cao Jiaming, Huabo Equipment, and others continue to invest. This round of financing will be mainly used to accelerate the clinical development of core small nucleic acid product pipelines, further optimize key technology platforms such as extrahepatic delivery, expand the preclinical product layout, and build the core team.